novo nordisk cagrilintide files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Larvol Delta
Larvol Delta Weight loss: New drug CagriSema leads to 14% weight loss in trial CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters
Pay in 4 interest-free payments of $6.40 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9


